BPN14770 (Zatolmilast) — Safety, Research, Risks & Legal Status

Not medical advice. BPN14770 (Zatolmilast) is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Zatolmilast, BPN-14770, BPN 14770
Category	Research Chemical
Drug class	Allosteric phosphodiesterase-4D (PDE4D) inhibitor, first-in-class
Developer	Tetra Discovery Partners / Tetra Therapeutics, acquired by Shionogi
Lead indication	Fragile X syndrome (also studied in Alzheimer's disease)
Trial stage	Phase 3 completed; primary endpoint not met (reported June 2026)
Route	Oral small molecule
US regulatory status	Investigational; Orphan Drug, Rare Pediatric Disease, and Fast Track designations; not approved
US legal status	Investigational drug in the United States. BPN14770 (zatolmilast) is not FDA-approved for any indication and is not a lawful dietary supplement or over-the-counter product. It is a new molecular entity studied under an Investigational New Drug (IND) framework in company-sponsored clinical trials (Tetra Discovery Partners / Tetra Therapeutics, now part of Shionogi). The FDA has granted it Orphan Drug, Rare Pediatric Disease, and Fast Track designations for Fragile X syndrome, but these are development incentives that do not indicate approval or establish efficacy. There is no lawful channel for consumer purchase; any material offered by gray-market vendors as a "research chemical not for human consumption" is unverified and sits outside all regulatory oversight.

What is BPN14770 (Zatolmilast)?

BPN14770, known by its proposed generic name zatolmilast, is a first-in-class, orally available small-molecule allosteric inhibitor of phosphodiesterase-4D (PDE4D). Rather than blocking the enzyme's catalytic site like older non-selective PDE4 inhibitors, it binds an allosteric regulatory region and only partially reduces PDE4D activity, an approach proposed to raise brain cyclic AMP (cAMP) signaling while limiting the nausea and emesis that historically constrained the PDE4 drug class. It has been developed principally as a candidate cognitive therapeutic for Fragile X syndrome (FXS), with additional exploration in Alzheimer's disease. It is an investigational compound only, with no approved therapeutic use.

How it works

PDE4D is one isoform of the phosphodiesterase-4 family that degrades cyclic AMP (cAMP), a second messenger central to synaptic plasticity, long-term potentiation, and memory consolidation. By allosterically and partially inhibiting PDE4D, BPN14770 is proposed to raise and prolong cAMP signaling in neurons, engaging the downstream cAMP-PKA-CREB pathway and, in preclinical reports, a cAMP/SIRT1/Akt/Bcl-2 cascade linked to neuronal survival. In Fragile X syndrome, loss of FMRP is thought to dysregulate this signaling and impair synaptic maturation; the proposed therapeutic rationale is that restoring cAMP tone promotes maturation and stabilization of neuronal connections. The allosteric, partial-inhibition mechanism (binding a regulatory region rather than fully blocking the catalytic site) is the design feature intended to preserve tolerability relative to earlier full PDE4 inhibitors. This mechanism is well characterized preclinically but its translation to durable human cognitive benefit was not confirmed in the Phase 3 trials.

Background & history

BPN14770 was discovered and developed by Tetra Discovery Partners (later Tetra Therapeutics), a Michigan-based biotech founded by Mark Gurney, as part of a program targeting allosteric modulation of PDE4D for cognitive disorders. FRAXA Research Foundation supported early Fragile X work. Positive Phase 2 topline results in FXS were reported in 2020, with peer-reviewed publication in Nature Medicine in 2021. Shionogi, a Japanese pharmaceutical company, acquired Tetra and advanced the compound (assigning the generic name zatolmilast) into the multicenter Phase 2b/3 EXPERIENCE program beginning in 2022. The FDA granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations. In June 2026 Shionogi announced that the pivotal Phase 3 trials missed their primary cognitive endpoint, a significant setback for what had been one of the most closely watched Fragile X drug candidates.

What the research says

Human data are limited but more extensive than for most compounds in this reference, and the most recent readout is negative on the primary goal. A single-center, randomized, placebo-controlled, two-period crossover Phase 2 study in 30 adult men with FXS (published in Nature Medicine in 2021) reported the drug was well tolerated and showed improvement on secondary cognitive measures, specifically NIH Toolbox language domains such as picture vocabulary and oral reading recognition, with corresponding caregiver-rated gains in language and daily function. Those Phase 2 findings were exploratory and hypothesis-generating in a small sample. The program then advanced to the multicenter Phase 2b/3 EXPERIENCE trials. In June 2026, Shionogi reported that both pivotal Phase 3 trials, EXPERIENCE-204 (adolescent males, 15 mg and 25 mg) and EXPERIENCE-301 (adult males, 25 mg), together enrolling roughly 334 participants, failed to meet their primary endpoint of improvement in the NIH Toolbox Cognition Crystallized Composite score after 13 weeks. A secondary, caregiver-reported FXS Numerical Rating Scale for language and daily function reached significance in the adult trial (EXPERIENCE-301) but not the adolescent trial. An open-label extension (EXPERIENCE-302) has been ongoing. Beyond FXS, a Phase 2 study was conducted in early Alzheimer's disease, and preclinical work spans scopolamine-induced cognitive deficit models and Fragile X mouse models. Net picture: promising early signals, mechanistically coherent, but the confirmatory efficacy bar was not cleared.

Reported effects

Proposed enhancement of memory formation and cognition via increased cAMP signaling (mechanism-based, not established in humans)
Signal toward improved language-domain cognition in Fragile X (positive on secondary, not primary, endpoints)
Caregiver-reported improvement in daily function and language in adult FXS (secondary endpoint, adult trial only)
Preclinical promotion of synaptic maturation and dendritic spine normalization in Fragile X models
Preclinical neuroprotection against amyloid-beta toxicity in Alzheimer's models
Generally well tolerated in trials, with the allosteric design intended to reduce PDE4-class nausea

Dosing & administration (informational)

Informational only, not a protocol and not dosing guidance. In the published and reported clinical trials, oral doses were in a low milligram range, with the Phase 3 EXPERIENCE studies using fixed doses of 15 mg and 25 mg (twice daily in the development program) selected by the sponsor after earlier dose-finding. These figures describe what appeared in monitored clinical research under medical supervision and eligibility screening; they are not a recommendation, are not validated for any use outside those trials, and say nothing about safety or appropriate dosing for an individual. There is no established dose for any approved indication because the drug is not approved.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Not an approved drug; long-term safety in any population is not established outside monitored trials
PDE4 inhibitors as a class are associated with nausea, vomiting, diarrhea, headache, and weight loss; the allosteric design aims to mitigate but not eliminate these
Older PDE4 inhibitors carry class concerns including psychiatric effects (mood changes, suicidal ideation) and vasculitis in animal models; relevance to a partial PDE4D-selective agent is uncertain
Trials were conducted in a specific population (mostly males with Fragile X syndrome); safety does not generalize to healthy adults, women, or other uses
Gray-market material has no verified identity, purity, or dose accuracy, adding contamination and mislabeling risk on top of the drug's own unknowns
No established drug-interaction profile in humans outside the trial setting
Self-experimentation with an investigational CNS drug forgoes the medical monitoring under which its safety data were generated

Drug & supplement interactions

Who should avoid it

Anyone outside a supervised clinical trial (there is no validated safe-use context for personal use)
People with psychiatric conditions, given PDE4-class signals for mood changes and suicidal ideation
Pregnant or breastfeeding individuals (no reproductive safety data)
Anyone taking other PDE inhibitors or cAMP-modulating CNS drugs without clinician oversight
People expecting an approved or proven cognitive enhancer (Phase 3 efficacy was not demonstrated)
Anyone relying on gray-market material of unverified identity and purity

How it is commonly combined

There is no evidence-based rationale for stacking an unapproved investigational PDE4D inhibitor with other compounds, and combining it with other CNS-active or cAMP-modulating substances compounds unknown risks rather than adding benefit. No nootropic "stack" has been studied with BPN14770 in humans. This reference does not endorse combining it with anything; the only context in which its combinations have been evaluated is formal clinical research.

Legal & regulatory. Investigational drug in the United States. BPN14770 (zatolmilast) is not FDA-approved for any indication and is not a lawful dietary supplement or over-the-counter product. It is a new molecular entity studied under an Investigational New Drug (IND) framework in company-sponsored clinical trials (Tetra Discovery Partners / Tetra Therapeutics, now part of Shionogi). The FDA has granted it Orphan Drug, Rare Pediatric Disease, and Fast Track designations for Fragile X syndrome, but these are development incentives that do not indicate approval or establish efficacy. There is no lawful channel for consumer purchase; any material offered by gray-market vendors as a "research chemical not for human consumption" is unverified and sits outside all regulatory oversight.

Quality & harm reduction

B
e
c
a
u
s
e
t
h
e
r
e
i
s
n
o
l
e
g
i
t
i
m
a
t
e
c
o
n
s
u
m
e
r
m
a
r
k
e
t
,
a
n
y
B
P
N
1
4
7
7
0
s
o
l
d
a
s
a
"
r
e
s
e
a
r
c
h
c
h
e
m
i
c
a
l
"
c
o
m
e
s
f
r
o
m
u
n
r
e
g
u
l
a
t
e
d
s
u
p
p
l
i
e
r
s
w
i
t
h
n
o
p
h
a
r
m
a
c
o
p
e
i
a
l
s
t
a
n
d
a
r
d
,
n
o
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
y
o
u
c
a
n
t
r
u
s
t
w
i
t
h
o
u
t
i
n
d
e
p
e
n
d
e
n
t
t
e
s
t
i
n
g
,
a
n
d
n
o
c
h
a
i
n
o
f
c
u
s
t
o
d
y
.
R
e
p
o
r
t
e
d
i
d
e
n
t
i
t
y
a
n
d
p
u
r
i
t
y
c
a
n
n
o
t
b
e
a
s
s
u
m
e
d
.
I
n
d
e
p
e
n
d
e
n
t
t
h
i
r
d
-
p
a
r
t
y
a
n
a
l
y
s
i
s
(
f
o
r
e
x
a
m
p
l
e
H
P
L
C
o
r
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
f
r
o
m
a
n
a
c
c
r
e
d
i
t
e
d
l
a
b
)
w
o
u
l
d
b
e
t
h
e
o
n
l
y
w
a
y
t
o
v
e
r
i
f
y
w
h
a
t
a
s
a
m
p
l
e
a
c
t
u
a
l
l
y
c
o
n
t
a
i
n
s
,
a
n
d
e
v
e
n
a
v
e
r
i
f
i
e
d
s
a
m
p
l
e
d
o
e
s
n
o
t
r
e
s
o
l
v
e
t
h
e
c
o
m
p
o
u
n
d
'
s
u
n
s
e
t
t
l
e
d
c
l
i
n
i
c
a
l
p
r
o
f
i
l
e
.
A
u
t
h
e
n
t
i
c
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
m
a
t
e
r
i
a
l
e
x
i
s
t
s
o
n
l
y
w
i
t
h
i
n
t
h
e
s
p
o
n
s
o
r
'
s
c
l
i
n
i
c
a
l
s
u
p
p
l
y
c
h
a
i
n
a
n
d
i
s
n
o
t
a
v
a
i
l
a
b
l
e
t
o
t
h
e
p
u
b
l
i
c
.

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find BPN14770 (Zatolmilast) →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Does BPN14770 actually improve cognition?

The evidence is mixed and ultimately unconfirmed at the confirmatory level. A small Phase 2 trial in adult men with Fragile X showed improvement on secondary language-related cognitive measures, but both pivotal Phase 3 EXPERIENCE trials failed to meet their primary cognitive endpoint in 2026. One secondary caregiver-reported measure was positive in the adult trial. There is no demonstrated cognitive benefit in healthy people.

Is it FDA-approved or available by prescription?

No. It is an investigational drug with Orphan Drug, Rare Pediatric Disease, and Fast Track designations but no FDA approval. It is not available by prescription and is not a legal supplement.

How is it different from older PDE4 inhibitors like roflumilast?

Older PDE4 inhibitors block the enzyme's active site fully and non-selectively, which drove dose-limiting nausea and vomiting. BPN14770 binds an allosteric site and only partially inhibits the PDE4D isoform, a design intended to raise brain cAMP with better tolerability. Whether that translates to a meaningful clinical advantage is not established.

Why did the Phase 3 trials fail if Phase 2 looked positive?

The Phase 2 result rested on secondary, exploratory endpoints in only 30 participants. Larger, better-powered confirmatory Phase 3 trials did not reproduce a benefit on the pre-specified primary cognitive endpoint. This pattern, where a small early signal does not hold up in pivotal testing, is common in CNS drug development.

Can I buy it to use as a nootropic?

There is no legal or verified way to obtain it for personal use. Any material sold as a research chemical is of unknown identity and purity, and self-experimenting with an investigational CNS drug forgoes the medical monitoring under which its limited safety data were generated. This reference is informational and does not sell or recommend using it.

What dose was used in the trials?

This is informational only and not dosing guidance. The Phase 3 EXPERIENCE studies used fixed oral doses of 15 mg and 25 mg selected by the sponsor after dose-finding, given under medical supervision to screened participants. That is not a protocol for personal use. Anyone with questions about their own situation should consult a qualified clinician.

References & further reading

PubMed: BPN14770 fragile X syndrome phase 2 randomized crossover
PubMed: BPN14770 PDE4D allosteric inhibitor cAMP cognition
PubMed: BPN14770 scopolamine cognitive deficit SIRT1 Akt
ClinicalTrials.gov: zatolmilast BPN14770 fragile X EXPERIENCE
ClinicalTrials.gov: BPN14770 Alzheimer disease phase 2